COMPUGROUP MEDSPADR (Germany) Performance
| COPA Stock | EUR 20.80 0.20 0.97% |
On a scale of 0 to 100, COMPUGROUP MEDSPADR holds a performance score of 10. The firm shows a Beta (market volatility) of 0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, COMPUGROUP MEDSPADR's returns are expected to increase less than the market. However, during the bear market, the loss of holding COMPUGROUP MEDSPADR is expected to be smaller as well. Please check COMPUGROUP MEDSPADR's coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to make a quick decision on whether COMPUGROUP MEDSPADR's price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in COMPUGROUP MEDSPADR 1 are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, COMPUGROUP MEDSPADR reported solid returns over the last few months and may actually be approaching a breakup point. ...more
COMPUGROUP |
COMPUGROUP MEDSPADR Relative Risk vs. Return Landscape
If you would invest 1,290 in COMPUGROUP MEDSPADR 1 on September 24, 2024 and sell it today you would earn a total of 790.00 from holding COMPUGROUP MEDSPADR 1 or generate 61.24% return on investment over 90 days. COMPUGROUP MEDSPADR 1 is generating 0.9395% of daily returns assuming 6.8615% volatility of returns over the 90 days investment horizon. Simply put, 61% of all stocks have less volatile historical return distribution than COMPUGROUP MEDSPADR, and 82% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
COMPUGROUP MEDSPADR Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for COMPUGROUP MEDSPADR's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as COMPUGROUP MEDSPADR 1, and traders can use it to determine the average amount a COMPUGROUP MEDSPADR's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1369
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | COPA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.86 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.94 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average COMPUGROUP MEDSPADR is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of COMPUGROUP MEDSPADR by adding it to a well-diversified portfolio.
COMPUGROUP MEDSPADR Fundamentals Growth
COMPUGROUP Stock prices reflect investors' perceptions of the future prospects and financial health of COMPUGROUP MEDSPADR, and COMPUGROUP MEDSPADR fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on COMPUGROUP Stock performance.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.031 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.08 % | |||
| Shares Outstanding | 52.23 M | |||
| Price To Earning | 53.50 X | |||
| Revenue | 1.13 B | |||
| EBITDA | 149.63 M | |||
| Cash And Equivalents | 91.45 M | |||
| Cash Per Share | 1.73 X | |||
| Total Debt | 685.04 M | |||
| Debt To Equity | 1.19 % | |||
| Book Value Per Share | 12.98 X | |||
| Cash Flow From Operations | 165.54 M | |||
| Earnings Per Share | 1.37 X | |||
About COMPUGROUP MEDSPADR Performance
By analyzing COMPUGROUP MEDSPADR's fundamental ratios, stakeholders can gain valuable insights into COMPUGROUP MEDSPADR's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if COMPUGROUP MEDSPADR has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if COMPUGROUP MEDSPADR has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. KGaA was founded in 1987 and is headquartered in Koblenz, Germany. COMPUGROUP MED is traded on Frankfurt Stock Exchange in Germany.Things to note about COMPUGROUP MEDSPADR performance evaluation
Checking the ongoing alerts about COMPUGROUP MEDSPADR for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for COMPUGROUP MEDSPADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| COMPUGROUP MEDSPADR is way too risky over 90 days horizon | |
| COMPUGROUP MEDSPADR appears to be risky and price may revert if volatility continues | |
| COMPUGROUP MEDSPADR 1 has accumulated 685.04 M in total debt with debt to equity ratio (D/E) of 1.19, which is about average as compared to similar companies. COMPUGROUP MEDSPADR has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist COMPUGROUP MEDSPADR until it has trouble settling it off, either with new capital or with free cash flow. So, COMPUGROUP MEDSPADR's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like COMPUGROUP MEDSPADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for COMPUGROUP to invest in growth at high rates of return. When we think about COMPUGROUP MEDSPADR's use of debt, we should always consider it together with cash and equity. |
- Analyzing COMPUGROUP MEDSPADR's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether COMPUGROUP MEDSPADR's stock is overvalued or undervalued compared to its peers.
- Examining COMPUGROUP MEDSPADR's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating COMPUGROUP MEDSPADR's management team can have a significant impact on its success or failure. Reviewing the track record and experience of COMPUGROUP MEDSPADR's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of COMPUGROUP MEDSPADR's stock. These opinions can provide insight into COMPUGROUP MEDSPADR's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for COMPUGROUP Stock analysis
When running COMPUGROUP MEDSPADR's price analysis, check to measure COMPUGROUP MEDSPADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COMPUGROUP MEDSPADR is operating at the current time. Most of COMPUGROUP MEDSPADR's value examination focuses on studying past and present price action to predict the probability of COMPUGROUP MEDSPADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COMPUGROUP MEDSPADR's price. Additionally, you may evaluate how the addition of COMPUGROUP MEDSPADR to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |